The Coronavirus pandemic is spreading across the globe at an exponential rate. The deadly virus has already infected more than 15 million people and the count is still increasing as we speak.
In this situation, scientists and international medical facilities are looking for possible COVID-19 treatment or vaccine. HBOT therapy is one such potential treatment, which gives promising results in severe and critical COVID-19 patients. The following sections would discuss the report launched by Dr. Yangling on HBOT treatment for COVID-19. Read more to get detailed insights into the situation.
What DO You Need To Know About Dr. Yangling’s Report?
In April, a report was released on the findings made by Dr. ZhongYangling on HBOT as a possible COVID-19 treatment. Dr. Yangling is the HBOT Department director of Wuhan Yangtze River Shipping General Hospital. Following his research, Dr. Yanglijng used HBOT therapy to treat severe COVID-19 cases. In fact, his research has triggered trials in many countries.
In his initial study, Dr. Yangling included 3 severe and 2 critical patients of COVID-19. Every patient of the study observed significant relief in symptoms after the initial session of HBOT therapy.
These patients were experiencing symptoms, including breathlessness, cough, fever, and along with warning signs like persistent chest pain, chest pressure, breathing issues, bluish face, confusion, etc. The virus was creating hypoxemia, low oxygen levels in the blood, in the patients, which increased the chances of ventilator support.
When HBOT therapy was given to these patients, the extra supply of oxygen helped in revealing hypoxemia. Generally, only red blood cells of the body are the carrier of oxygen in the body. In an HBOT chamber, the pressure is increased and more oxygen is delivered to the body. The oxygen dissolves in body fluids such as lipids, plasma, and cerebral-spinal fluids. Due to this, oxygen passes through thick walls of highly inflamed tissues around the lungs. Hence, offering a direct treatment of hypoxemia.
In this trial, patients received oxygen at 1.4-1.6 ATA for 90-120 minutes.
- The first session decreased labored breathing or dyspnea and pain in the chest.
- The second session improved the rate of respiration and relived breathlessness.
- Finally, all the sessions improved gastrointestinal, appetite, inflammation, and headache-related, and other less severe symptoms.
Dr. Yangling, thus, confirmed that HBOT could help severe and critical COVID-19 patients without creating uncontrollable risks. If the therapy is received under guidance by expert medical professionals, it can be effective in the case of COVID-19.
HBOT Therapy for COVID-19
This report by Dr. Yangling has empowered the entire medical community to observe the effectiveness of HBOT in COVID-19. As a result, multiple experts have confirmed that using HBOT chambers can offer support to individuals who are suffering from hypoxemia and breathing issues.
For instance, in Sweden and Germany, clinical trials are being conducted to understand the potential of COVID-19. It is a controlled randomized trial, which is studying if HBOT can decrease hospitalization.
In Israel, another study is being conducted with 30 patients who will become a part of the double-blind, controlled, and randomized trial. Patients would receive either eight sessions at 1.0 ATA and 100% oxygen or a similar number of HBOT sessions at 2.2 ATA and 100% oxygen.
France has also released its statement explaining that the major aim of conducting this research is assessing HBOT’s effectiveness in COVID-19. It is necessary to understand how HBOT therapy can help COVID-19 patients to decrease the dependence of ventilator and reduce pneumonia symptoms through non-invasive procedures. The study is being conducted to know how much time a patient needs to recover normal breathing, including ventilation days, mortality rate, etc.
In yet another trial happening in Mineola, the safety of using HBOT therapy in case of COVID-19 critical cases is being assessed. The scientists are trying to use HBOT therapy as an emergency option to treat severe cases at 2.0 AATA and 100% oxygen for 90 minutes.
Another trial in the US is now inviting candidates to enroll for the therapy. The trial will strictly focus on the methods to reduce the ventilation of patients suffering from COVID-19.
In severe and critical cases, COVID-19 impacts the lungs of the individual and reduces the efficiency of breathing. This leads to labored breathing. HBOT therapy can provide 100% oxygen to the lungs and reduce hypoxemia internally. This is why the research on this potential treatment is still being carried out.
However, it is necessary to note that it is not advisable to consider home HBOT units for treatment. Only authorized HBOT centers should be considered to receive the therapy at the right pressure and to avoid the unnecessary spread of the virus to other people. Hence, consult a specialist for better care and optimum treatment options.